Skyrizi
Skyrizi indication Expanded for Crohn’s Disease Treatment
AbbVie announced the FDA’s approval of Skyrizi as the first specific interleukin-23 inhibitor for treatment ...
JULY 5, 2022
FDA Grants Second Indication for Skyrizi
Risankizumab-rzaa is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 ...
JANUARY 24, 2022
Extended Risankizumab Induction Needed for Some Patients
Some Crohn’s disease patients may require 24 weeks before experiencing a response to treatment with ...
JANUARY 5, 2022
Load more